UTopiAH’s life expectancy and death rate are below the Marijuana states, which as of 2017, filled the top quintile state rankings. See Part 16. These parts contain the 2015 Drug Enforcement Agency’s response to a 2011 petition from the Governors of Washington and Rhode Island to legalize Marijuana, a DEA Schedule One Drug. . The letter is viewable at https://www.deadiversion.usdoj.gov/schedules/marijuana/Incoming_Letter_Department%20_HHS.pdf#search=marijuana.

[Continued from Part 37]

Part 38 Marijuana references for Schedule One of the Controlled Substances Act Drug Enforcement Agency, Controlled Substance Staff, Center for Drug Evaluation and Research, Food and Drug Administration.

REFERENCES

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik T A, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo­ controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66.

Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, and Petersen KL. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68 (7): 515-521.

Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 1996, 91(11):1585-1614.

Agurell, S., Dewey, W.L., and Willett, R.E., eds. The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects. New York: Academic Press, 1984.

Agurell, S.; Halldin, M.; Lindgren, J.E.; Ohlsson, A.; Widman, M.; Gillespie, H.; and Hollister, L. Pharmacokinetics and metabolism of delta 9-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacal Rev 1986, 38(1), 21-43.

Almirez RG, Smith CG, Asch RH. The effects of marijuana extract and delta 9­ tetrahydrocannabinol on luteal function in the rhesus monkey. Fertil Steril. 1983 Feb; 39(2):212­ 7.

Ameri, A. The effects of cannabinoids on the brain. Progress in Neurobiology 1999, 58 (4), 315-348.

American Academy ofPain Medicine, American Pain Society and American Society of Addiction Medicine Consensus Document. Definitions related to the use of opioids for the treatment of pain. 2001.

Andreassen S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study o f Swedish conscripts. Lancet. 1987 Dec 26;2(8574):1483-6.

Appendino G, Chianese G, Taglialatela-Scafati 0. Cannabinoids: occurrence and medicinal · chemistry. Curr Med Chern. 2011;18(7):1085-99.

AschRH, SmithCG, Siler-KhodrTM, PauersteinCJ. Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey(Macacamulatta). JClin Endocrinol Metab.

1981 Jan;52(1):50-5.
Balster, R.L., Prescott, W.R., delta 9-Tetrahydrocannabinol discrimination in rats as a model for

9
cannabis intoxication. Neurosci. & Biobehav. Rev. 1992, 16(1), 55-62.

[Page 40]

Balster RL and Bigelow GE. Guidelines arid methodological reviews concerning drug abuse liability assessment. Drug and Alcohol Dependence. 2003; 70: S13-S40.

Barnett, G.; Licko, V .; and Thompson, T. Behavioral pharmacokinetics o f marijuana. Psychopharmacology 1985, 85(1), 51-56.

Battista N, Di TM, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front. Behav. Neurosci. 2012;6:9.

Benowitz NL, Jones RT. Cardiovascular effects o f prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol   Ther. 1975 Sep; 18(3):287-97.

Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacal. 1981 Aug-Sep; 21(8-9 Suppl):214S-223S.

BlockRl, FarinpourR, SchlechteJA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend. 1991 Aug; 28(2):121-8.

Block Rl, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacal Biochem Behav. 1992 Nov; 43(3):907-17.

Bolla KI, Brown K, Eldreth D, Tate K, and Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002 59:1337-1343.

Bolla Kl, Eldreth DA, Matochik JA, and Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neurolmage 2005 26:480-492.

Bonnet U. Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. Pharmacopsychiatry. 2013 Jan;46(1):35-6.

Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993 May 15; 214(1 ): 173-80.

Braida D, Iosue S, Pegorini S, Sala M. Delta 9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur JPharmacal. 2004 Dec3; 506(1):63-9.

Breivogel CS, Childers SR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacal Exp Ther. 2000 Oct; 295(1):328-36.

Breivogel CS, GriffinG, DiMarzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacal. 2001 Jul; 60(1):155-63.

[page 41]

Brown TT, Dabs AS. Endocrine effects of marijuana. J Clin Pharmacal. 2002 Nov; 42(11 Suppl):90S-96S.

Browne RG, Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacal. 1981 Aug-Sep; 21(8-9 Suppl):227S-234S.

Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov;161(11):1967-77.

Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006 May;19(3):233-8.

Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursae Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst. Abuse Treat. 2008 Dec;35(4):362-8.

Capriotti RM, Foltin RW, Brady JV, Fischman MW. Effects of marijuana on the task-elicited physiological response. Drug Alcohol Depend. 1988 Jul; 21(3):183-7.

Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Delta 9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2012 Mar;5(1 ):32-40.

Chait LD. Subjective and behavioral effects of marijuana the morning after smoking. Psychopharmacology (Berl.) 1990;100(3):328-33.

Chait LD, Burke KA. Preference for high- versus low-potency marijuana. Pharmacal Biochem Behav. 1994 Nov;49(3):643-7.

Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl). 1998 Feb; 135(4):324-32.

Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl). 2000 Jul;151(1):25-30.

Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacal Biochem Behav.1986 Jun; 24(6):1749-54.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, and Gouaux B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ184 (10): 1143-1150.

Council on Science and Public Health Report 3. Use of cannabis for medicinal purposes. American Medical Association, Interim Meeting, Houston, Texas; November 2009.

[page 42]

Crawford WJ, and Merritt JC. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. International journal of clinical pharmacology and biopharmacy 17 (5): 191-196.

Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol. 2005 Sep; 166(1-2):3-18. Review.

Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9­ tetrahydrocannabinol effects. Clin. Pharmacol. Ther. 1976 Mar;19(3):300-9.

Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene­ tetrahydrocannabinol on hormone release and immune function. J Steroid Biochem. 1989; 34(1­ 6):263-70.

Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003 Jul20; 71(1):37-48.

Degenhardt L, Chiu WT, Conway K, Dierker L, Glantz M, Kalaydjian A, Merikangas K, Sampson N, Swendsen J, Kessler RC. Does the ‘gateway’ matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychol.Med 2009 Jan;39(1):157-67.

Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N, Alonso J, Angermeyer M, Anthony JC, Bruffaerts R, et al. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol. Depend. 2010 Apr

1; 108(1-2):84-97.

Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, Fratta W. Strain and schedule­ dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology. 2007 Feb;52(2):646-54.

Dewey, W. L., Martin, B. R., May, E. L. Cannabinoid stereoisomers: pharmacological effects. In Smith, D. F. (Ed.) CRC Handbook of stereoisomers: drugs in psychopharmacology, 317-326 (Boca Raton, FL, CRC Press), 1984.

DiMarzo, V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends. Pharmacol. Sci 2006 Mar;27(3):134-40.

DEA Statistics and Facts. (n.d.) DEA Domestic Drug Seizures. http://www.justice.gov/dea/resource-center/statistics.shtml/ (accessed August 5, 2014)

Drug Enforcement Administration, Drugs of Abuse, 2005.
Drug Enforcement Administration. Sourcebook of Criminal Justice Statistics, 2003.

DSM-V.DiagnosticandStatisticalManualofMentalDisorders,FifthEdition. American Psychiatric Association. Washington, DC: American Psychiatric Publishing, 2013.

[page 43 ]

Eldridge JC, Murphy LL, Landfield PW. Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. Steroids. 1991·May; 56(5):226-31. Review.

Ellis RJ, ToperoffW, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, Bentley H, and Atkinson JH. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 34 (3): 672-680.

ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sciences. 2005; 78:539-48.

Fant RV, Heishman SJ, Bunker EB, Pickworth WB. Acute and residual effects of marijuana in humans. Pharmacal Biochem Behav. 1998 Aug; 60(4):777-84.

Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br.J Pharmacal. 2007
Nov; 152(5):795-804.

Fergusson DM, Horwood LJ, Ridder EM.Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005 Mar;100(3):354-66.

Fontes MA, Bolla Ki, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR Bressan RA, Lacerda

7. Cannabis use before age 15 and subsequent executive functioning. Br.J Psychiatry 2011 Jun;l98(6):442-7.

Fried, P. A., Watkinson, B. 36- and 48-month neurobehabioral follow-up of children prenatally exposed to marijuana, cigarettes and alcohol. J. Dev. Behav. Pediatr. 1987, 8, 318-326.

Fried,P.A.,Watkinson,B.,Gray,R. A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes and alcohol. Neurotoxicol. Teratol. 1992, 14, 299-311.

Fried, P. A., Watkinson, B., Gray, R. Differential effects on cognitive functioning in 9- to 12­ year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 1998, 20(3), 293-306.

Fried PA. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. J.Clin.Pharmacol. 2002 Nov;42(11 Suppl):97S-102S.

Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana–a comparison with pre-drug performance. Neurotoxicol.Teratol. 2005 Mar;27(2):231-9.

Fung,M.,Gallagher,C.,Machtay,M. Lungandaeo- digestive cancers in young marijuana smokers. Tumori 1999, 85 (2), 140-142.

[page 44]

Galiegue S, MaryS, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral canriabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1):54-61.

Gaoni, Y., Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chern. Soc. 1964,86, 1646-1947.

Gerard, C. M., Mollereau, C., Vassart, G., Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis.: Biochem J. 1991,279, 129-34.

Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci. 2002 Feb 1;22(3): 1146-54.

Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rhesus monkeys. J Pharmacol Exp Ther. 1992 Aug;262(2):479-86.

Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J.Am. Acad. Child. Adolesc. Psychiatry. 2008 Mar;47(3):254-63.

Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Phannacol Ther. 1984 Jan;35(1 ):26-32.

Gong JP , Onaivi ES, Ishiguro H, Liu QR, Tagliaferro P A, Brusco A, Uhl GR. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 2006 Feb 3;1071(1):10-23

Gonsiorek W, Lunn C, Fan X,Narula S, Lundell D, Hipkin RW. Endocannabinoid 2­
arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by · anandamide. Mol Pharmacol. 2000 May;57(5):1045-50.

Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol.Rev. 2007 Sep;17(3):347-61.

Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol. Biochem. Behav. 2005 Jun;81(2):300-18.

Grant I. Foreword by Igor Grant, M.D., Director, Center for Medicinal Cannabis Research (CMCR). Neuropharmacology. 2005 Jun; 48(8): 1067.

Griffith-Lendering MF, Wigman JT, Prince van LA, Huijbregts SC, Huizink AC, Ormel J, Verhulst FC, van OJ, Swaab H, Vollebergh WA. Cannabis use and vulnerability for psychosis in early adolescence-a TRAILS study. Addiction 2012 Dec 7.

[page 45]

Grotenhermen F. Pharmacokinetics and pharmaco dynamics of cannabinoids. Clin

Pharmacokinet. 2003;42(4):327-60.

Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol. Addict. Behav. 2012 Sep;26(3):496-506.

Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 2005 Jan;24(1):39­ 48.

Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, and Foltin RW. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. Journal of acquired immune deficiency syndromes (1999) 45 (5): 545-554.

Haney M, Rabkin J, Gunderson E, and Foltin RW. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 181 (1): 170­ 178.

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999, 141(4):395-404

Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Roos, R. A., Mechoulam, R., Pride, E. HU-308: a specific agonist for CB(2), a peripheral Cannabinoid receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 14228-33.

Heishan SJ, Huestis MA, Benningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacal Biochem Behav. 1990 Nov;37(3):561-5.

Herkenham, M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems. In: Kalivas, P.W., and Samson, B.H., eds. The neurobiology of drug and alcohol addiction. Ann NY Acad Sci 1992, 654, 19-32.

Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., Rice, K. C. Cannabinoid receptor localization in Brain. Proc. Natl. Acad. Sci. U S A. 1990, 87, 1932­

Heming, R.I.; Hooker, W.D.; and Jones, R.T. Tetrahydrocannabinol content and differences in marijuana smoking behavior. Psychopharmacology 1986,90(2):160-162.

Billig, K.W. Genetic evidence for speciation in Cannabis (Cannabaceae). Genetic Resources and Crop Evolution 52: 161-180,2005.

Hirvonen, J., Goodwin, R. S., Li, C. T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N.D., Huestis, M.A., Innis, R. B. Reversible and regionally selective downregulation of brain cannabinoid CB I receptors in chronic daily cannabis smokers. Mol. Psychiatry. 2012(Jun), 17(6), 643-649.

[page 46]

Oiveru. R. L., Mosher, W. A., Hoffman, F. W. Isolation oftrans-l-tetrahydrocannabinol from marihuana. 1. Am. Chern. Soc. 1966, 88, 1832-1833.

Hollister LE, Gillespie HK. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. Clin. Pharmacol.T her. 1973 May; 14(3):353-7.

Hollister, L.E. Health aspects of cannabis. PharmacologicalRev. 1986, 38, 1-20.

Hollister, L.E. Cannabis. (Literature review). Acta Psychiatr Scand (Suppl) 1988, 78, 108-118.

Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ.
Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47 Suppl I :345-58

Huestis, M.A., Sampson, A. H., Holicky, B. 1., Henningfield, 1. E., Cone, E. 1. Characterization of the absorption phase of marijuana smoking. Clin. Pharmacal. Ther. 1992a, 52, 31-41.

Huestis, M.A.; Henningfield, J.E.; and Cone, E.J. Blood Cannabinoids. 1. Absorption of THC and formation of 11-0H-THC and THC COOH during and after smoking marijuana. 1 Anal Toxicol1992b, 16(5), 276-282.

Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacal Exp Ther. 1980 Oct;215(1 ):35-44.

Ilan AB, Gevins A, Coleman M, Elsohly MA, de WH. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav.Pharmacal. 2005 Sep;16(5­ 6):487-96.

Institute of Medicine. Division of Health Sciences Policy. Marijuana and Health: Report of a Study by 1:\ Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.

Institute of Medicine, Division of Neuroscience and Behavioral Health. Marijuana and Medicine: Assessing the Science Base. Washington D.C.: National Academy Press, 1999.

Johansson, E.; Halldin, M.M.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Terminal elimination plasma half-life of delta 9-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur Clin Pharmacal 1989,37(3),273-277.

Johnston, L. D., O’Malley, P.M., Miech, R. A., Bachman, 1. G., & Schulenberg, J. E. (2014). Monitoring the Future national survey results on drug use: 1975-2013: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan, 84pp.

[page 47]

Jones, R.T.; Benowitz, N.L.; and Heming, R.I. Clinical relevance of cannabis tolerance and dependence. J Clin Phannacoll981, 21,143S-152S.

Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacal. 2002 Nov;42(11 Suppl):58S-63S.

Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacal Biochem Behav. 2005 Jun; 81(2): 285-299.

Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta 9­ tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003 Sep;l69(2): 135-40

Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology.(Berl.) 2004 Apr;173(1-2):186-94.

Kandel, D. Stages in adolescent involvement in drug use. Science 1975; 190:912-914.

Kandel DB, Chen K. Types of marijuana users by longitudinal course. J Stud Alcohol. 2000 May;61(3):367-78.

Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9- tetrahydrocannabinol in man. Eur.J Pharmacal. 1974 Sep;28(1):172-7.

Kamiol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE. Effects of delta 9­ tetrahydrocannabinol and cannabinol in man. Pharmacology 1975;13(6):502-12.

Kirk JM, de Wit H. Responses to oral delta 9-tetrahydrocannabinol in frequent and infrequent marijuana users. Phartnacol Biochem Behav. 1999 May;63(1):137-42.

Kuepper R, van OJ, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011 ;342:d738.

Kurzthaler I, Hummer M, Miller C, Spemer-Unterweger B, Gunther V, Wechdorn H, Battista HJ, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry. 1999 Jun;60(6):395-9. ·

Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. Expert Rev. Respir.Med 2011 Aug;5(4):537-46.

Lemberger L., Silberstein, S.D., Axelrod,J.,Kopin,I.J. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 1970, 170, 1320-1322.

[page 48]

Lemberger L., Weiss, J. L., Watanabe, A.M., Galanter, I. M., Wyatt, R. J., Cardon, P. V. Delta- 9-tetrahydrocannabinol: temporal correlation of the psychological effects and blood levels after various routes of administration. New Eng. J. Med. 1972a, 286(13), 685-688.

9
Lemberger, L., Crabtree, R. E., Rowe, H. M. 11-Hydroxy-) -tetrahydrocarmabinol:

pharmacology, disposition and metabolism of a major metabolite of marihuana in man. Science 1972b, 177, 62-63.

Lemberger L., Rubin A. The physiologic disposition of marihuana in man, Life Sci. 1975,17, 1637-42.

LiM-C., Brady, J. E., DiMaggio, C. J., Lusardi, A. R., Tzong, K. Y ., Li, G. Marijuana use and motor vehicle crashes. Epidemiologic Reviews. 2012, 34, 65-72.

Liguori A, Gatto CP, Robinson JH. Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. Behav Pharmacal. 1998 Nov; 9(7):599-609.

Lile JA, Kelly TH, Hays LR. Separate and combined effects of the carmabinoid agonists nabilone and Delta(9)-THC in humans discriminating Delta(9)-THC. Drug Alcohol Depend. 2011 Jul1;116(1-3):86-92.

Lile JA, Kelly TH, Pinsky DJ, Hays LR. Substitution profile of Delta 9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta 9­ tetrahydrocannabinol. Psychopharmacology (Berl.) 2009 Apr;203(2):241-50.

Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol.Soc 2012 Jul;18(4):678-88.

Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT. Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med. 2004 Oct;34(7):1239-50.

Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in At T20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995 Oct;15(10):6552-61 .

Maldonado R. Study of cannabinoid dependence in animals. Phannacol Ther. 2002 Aug;95(2): 153-64.

Malinowska B, Baranowska-Kuczko M, Schlicker E. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br.J Pharmacol 2012 Apr; 165(7):2073-88.

Manrique-Garcia E, Zammit S, Dalman C, Hernmingsson T, Andreassen S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol. Med 2012 Jun;42(6): 1321-8.

[page 49]

Maremmni I, Lazzeri A, Pacini M, Lovrecic M, Placidi GF, Perugi G. Diagnostic and · symptomatological features in chronic psychotic patients according to cannabis use status. J Psychoactive Drugs. 2004 Jun;36(2):235-41.

“Marijuana Scheduling Petition; Denial of Petition; Remand; Final Order,” 57 Federal Register 59 (26 March 1992), pp. 10499- 10508.

[Ed. Petitions were submitted in 2011 to the DEA, by Governors Chafee of Rhode Island and Gregoire of Washington, to repeal rules placing Marijuana in Schedule I of the Controlled Substance Act, contending it is accepted and safe for medical use, with low abuse potential. The DEA Administrator requested HHS evaluate scientific and medical information with recommendations. The Secretary HHS, Controlled Substance Staff, Center for Drug Evaluation and Research, FDA replied to the DEA in 2015.]

Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W.Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience. 1998 Jul;85(2):327-30.

Matsuda, L.A., Lolait, S. J., Brownstein, M. J., Young, A. C., Bonner, T.I. Structure ofa cannabinoid receptor and functional expression of the cloned eDNA. Nature 1990, 346, 561­ 564.

McMahon LR. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta 9-tetrahydrocannabinol. Psychopharmacology (Berl.) 2009 Apr; 203(2):219-28.

McMahon LR, Ginsburg BC, Lamb RJ. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl.) 2008 Jul; 198(4):487-95.

Mechoulam, R. Cannabinoid chemistry. In Mechoulam, R. (ED.) Marijuana, pp.2-88 (New York, NY, Academic Press, Inc.), 1973.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol–recent advances. Chem.Biodivers. 2007 Aug;4(8):1678-92.

Mechoulam R, Shvo Y. Hashish-l: The structure of Cannabidiol. Tetrahedron. 1963; 19:2073­ 78.

Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly
MA. Potency Trends of Delta 9 – THC and other caimabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010 Sept; 55(5): 1209-1217.

Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad.Sci U.S.A 2012 Oct 2;109(40):E2657-E2664.

Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJ, Meijer CJ. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol.Med 2012 Apr;42(4):705-16.

Mendelson JH, Mello NK. Effects of marijuana on neuroendocrine hormones in human males and females. NIDA Res Monogr. 1984;44:97-114.

[page 50]

Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan lA, Ross SA. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod. 2009 May 22;72(5):906-11.

Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004 Feb 7;73(2): 109-19. ·

Ramaekers JG, Kauert G, van RP, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006 Oct;31 (1 0):2296-303.

Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J. Psychopharmacol. 2009 May;23(3):266-77.

Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. 9

Cognition and motor control as a function of Delta 9 -THC concentration in serum and oral fluid: Limits of impairment. Drug and Alcohol Dependence. 2006; 85: 1114-122.

“Rescheduling of the Food and Drug Administration Approved Product Containing Synthetic

9
Dronabinol [(-)-delta 9-(trans)-Tetrahydrocannabinol) in Sesame Oil and Encapsulated in Soft

Gelatin Capsules From Schedule II to Schedule III; Final Rule,” 64 Federal Register 127 (2 Ju1y 1999), pp. 35928 – 35930.

Riggs PK, Vaida F, Rossi SS, Sorkin LS, Gouaux B, Grant I, Ellis RJ. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 2012 Jan 11;1431 :46-52.

Rodriguez de Fonseca F, Gorriti, M.A., Femandez-Ruiz, J.J., Palomo, T., Ramos, J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9­ tetrahydrocannabinoil treatment. Phamacol. Biochem. Behav. 1994,47 (1), 33-40.

Roth MD, Tashkin DP, Whittaker KM, ChoiR, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci. 2005 Aug 19;77(14):1711-22.

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64.

Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment o f prostate cancer. Cancer Res. 2005 Mar 1;65(5): 1635-41.

Sanudo-Pena M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., Walker, J. M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett., 223, 125-128, 1997.

[page 52]

Mendizabal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology. 2006 Sep;31(9):1957-66.

Merritt JC, Crawford WJ, Alexander PC, Anduze AL, and Gelbart SS. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87 (3): 222-228.

Messinis L, Kyprianidou A, Malefaki S, and Papathanasopoulos P. Neuropsychological deficits in long-term frequent cannabis users. Neurology 2006 66:737-739.

Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev. 2010 May;29(3):304-17.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, and Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001; 103: 2805-2809.

Nace EP, Meyers AL, Rothberg JM, Maleson F. Addicted and nonaddicted drug users. A comparison of drug usage patterns. Arch Gen Psychiatry.1975;32(1):77-80.

Oviedo, A., Glowa, J., Herkenham, M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 1993, 616,293­ 302.

Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol.Rev. 2006 Sep;58(3):389-462.

Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Facorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des. 2012;18(32):5024­ 35.

Petrocellis PL, DiMarzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2009 Feb;23(1 ): 1-15.

Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs. 2005 Ju1;6(7):672-9.

Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012 Jan

11;307{2):173-81.

Pollastro F, Taglialatela-Scafati 0, Allara M, Munoz E, DiMarzo V, De Petrocellis L, Appendino G. Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa). J Nat Prod. 2011 Sep 23;74(9):2019-22

Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long­ term cannabis users. J Clin Phannacol. 2002 Nov;42(11 Suppl):41S-47S. Review.

[page 51]

Scherrer JF, Grant JD, Duncan AE, Sartor CE, Haber JR, Jacob T, Bucholz KK. Subjective effects to cannabis are associated with use, abuse and dependence after adjusting for genetic and environmental influences. Drug Alcohol Depend. 2009 Nov 1; 105(1-2):76-82.

Schiffman J, Nakamura B, Earleywine Ml LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Res. 2005 Mar 30;134(1):37-42.

Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp.Clin Psychopharmacol. 2012 Oct;20(5):420-9.

Sidney S. Cardio vascular consequences of marijuana use. JClinPharmacal.2002Nov;42(11 Suppl):64S-70S.

Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J; Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002 Mar 6;287(9):1123-31.

Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005 Jun 1;75(1):135-7.

Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.

Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series HA6, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2001-2011. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-65, HHS Publication No. (SMA) 13-4772. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.

Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 2011 Dec;106(12):2195-203.

Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology. 2010 Aug;215(8):588-97.

Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000 Nov;3(11):1073­ 4.

[page 53]

Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. 2005 Jun;63(2):93-1 00.

Tashkin DP, Shapiro BJ, and Frank IM. 1974. Acute effects of smoked marijuana and oral delta 9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. The American review of respiratory disease 109 (4): 420-428.

Tashkin, DP, Zhang, ZF, Greenland, S, Cozen, W, Mack, TM, Morgenstern, H. Marijuana Use and Lung Cancer: Results of a Case-Control Study. Abstract #A777, American Thoracic Society meeting, May 24, 2006.

The Plant List (201 0). Version 1. Published on the Internet; http://www.theplantlist.org/ (accessed September 20, 2013)

Theunissen EL, Kauert GF, Toennes SW, Moeller MR, Sambeth A, Blanchard MM, Ramaekers JG. Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology.(Berl.) 2012 Mar;220(2):341~50.

Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ cell tumors. Cancer. 2011 Feb 15;117: 848-853.

Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampalneurons. JNeurophysiol.1997 Jul;78(1):43-50.

van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de HL. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des. 2012;18(32):5036-44.

van Gastel WA, Wigrnan JT, Monshouwer K, Kahn RS, van OJ, Boks MP, Vollebergh WA. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. Addiction 2012 Feb;107(2):381-7.

Van Gundy K, Rebellon CJ. A Life-course Perspective on the “Gateway Hypothesis.” J Health Soc Behav. 2010 Sep;51(3):244-59.

van Os J, Bak M, Hanssen M, Bijl RV, de GraafR, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002 Aug 15;156(4):319-27.

Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco withdrawal. Am J Addict. 2005 Jan-Feb;14(1):54-63.

Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend. 2008 Jan 1;92(1-3):48-54.

[page 54]

Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)­ tetrahydrocannabinol. Drug Alcohol. Depend. 2008 Apr 1;94(1-3):191-8.

Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, MaherBS, IaconoWG, BierutL, NealeMC, ClarkDB, RidenourTA. Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective: Drug Alcohol Depend. 2012 Jun;123 Suppl l:S3-17

von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination o f risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend. 2002 Sep
1;68(1 ):49-64.

Wachtel SR, EISohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl). 2002 Jun;16I(4):331-9

Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med. 1998 Nov-Dec;76(12):824-36.

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, and Collet JP. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ: Canadian Medical Association journal =journal de l’Association medicale canadienne 182 (14): E694-E701.

Wesson DR, Washburn P. Current patterns of drug abuse that involve smoking. NIDA.Res.Monogr. 1990;99:5-11.

Wiley JL, Barrett RL, Britt DT, Balster RL, Martin BR. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology. 1993 Apr;32(4):359-65. ·

Wiley JL, Huffman JW , Balster RL, Martin BR. Pharmacological specificity o f the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 1995 Nov;40(1):81-6.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, and Donaghe H. 2013. Low-Dose

Vaporized Cannabis Significantly Improves Neuropathic Pain. The journal of pain : official journal of the American Pain Society.

Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, and Fishman S. 2008. A

randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The journal of pain : official journal of the American Pain Society 9 (6): 506-521.

Wu X, French ED. Effects of chronic delta 9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology. 2000 Jan 28;39(3):391-8.

[page 55]

Yucel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, Conus P, Takagi MJ, Fomito A, Wood SJ, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr.Bull. 2012 Mar;38(2):316-30.

Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, Hopfer CJ, Stallings MC, Young SE, Rhee SH. Subjective effects to marijuana associated with marijuana use in community and clinical subjects. Drug Alcohol Depend. 2010 Jun 1;109(1-3):161-6.

Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, Hsu TC, Schantz SP. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1071-8.

Zuardi A W, Shirakawa I, Finkelfarb E, Kamiol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl.) 1982;76(3):245-50.

[page 56]

Addiction Research Center Inventory [ARCI)

adenosine triphosphate (ATP)

adrenocorticotropic hormone (ACTH),

biologics license application (BLA)

cannabinoid receptor type 1 (CB1)

cannabichromene (CBC)

cannabidiol (CBD)

cannabinol (CBN)

Conditioned place preference (CPP)

Controlled Substances Act (CSA)

Controlled Substance Staff, Center for Drug Evaluation and Research, FDA

delta 9-THC

Diagnostic and Statistical Manual (DSM-5)

Drug Abuse Warning Network (DAWN) SAMHSA

Emergency Department [ED]

FDA Center for Drug Evaluation and Research

Food and Drug Administration (FDA)

U.S. Department of Health and Human Services (HHS)

International Classification of Diseases (ICD-10

[Investigational new drug] IND

IQ Intelligence Quotient

Monitoring the Future (MTF) survey

National Institutes of Health’s National Institute on Drug Abuse (NIH/NIDA)

[National Survey on Drug Use and Health] (NSDUH)

[new drug application] NDA

NMDA antagonists; N-Methyl-D-aspartate -anesthetics that antagonize, or inhibit the action

Substance Abuse and Mental Health Services Administration (SAMHSA)

System to Retrieve Information from, Drug Evidence (STRIDE) DEA’s

tetrahydrocannabinol (THC)

Treatment Episode Data Set (TEDS) 2011

[Continued next Part 39]

Disclaimer: The author of each article published on this web site owns his or her own words. The opinions, beliefs and viewpoints expressed by the various authors and forum participants on this site do not necessarily reflect the opinions, beliefs and viewpoints of Utah Standard News or official policies of the USN and may actually reflect positions that USN actively opposes. No claim in public domain or fair use. UTopiAH is a trade mark of the author. Utopia was written in 1516 by Sir Thomas More, Chancellor of England. © Edmunds Tucker.